Aviceda Therapeutics
Kevin Hambly is an experienced business and strategy professional with a strong background in the biotechnology sector. Currently serving as a Business/Strategy Advisor at Aviceda Therapeutics, Kevin has previously held key positions such as Chief Business Officer at ProfoundBio and Vice President of Corporate Development & Strategy at Eliem Therapeutics. Additionally, Kevin has worked as Vice President of Business Development at Nutcracker Therapeutics and served as the Head of Business Development at Alder BioPharmaceuticals, Inc. Kevin's comprehensive expertise in business development and strategy emphasizes a commitment to driving innovation in the life sciences industry.
This person is not in any teams
This person is not in any offices
Aviceda Therapeutics
1 followers
Aviceda Therapeutics is a late-stage, pre-clinical stage biotech company focused on the next generation of immuno-modulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly.